Tempest Therapeutics Statistics
Total Valuation
TPST has a market cap or net worth of $37.55 million. The enterprise value is $33.17 million.
Important Dates
The next estimated earnings date is Tuesday, March 18, 2025, after market close.
| Earnings Date | Mar 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPST has 43.64 million shares outstanding. The number of shares has increased by 61.11% in one year.
| Current Share Class | 43.64M |
| Shares Outstanding | 43.64M |
| Shares Change (YoY) | +61.11% |
| Shares Change (QoQ) | +14.46% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 7.57% |
| Float | 40.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.00 |
| P/TBV Ratio | 3.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 1.55.
| Current Ratio | 1.69 |
| Quick Ratio | 1.58 |
| Debt / Equity | 1.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.63 |
Financial Efficiency
Return on equity (ROE) is -691.89% and return on invested capital (ROIC) is -90.85%.
| Return on Equity (ROE) | -691.89% |
| Return on Assets (ROA) | -77.01% |
| Return on Invested Capital (ROIC) | -90.85% |
| Return on Capital Employed (ROCE) | -179.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.09M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.75% in the last 52 weeks. The beta is -2.66, so TPST's price volatility has been lower than the market average.
| Beta (5Y) | -2.66 |
| 52-Week Price Change | -76.75% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 40.89 |
| Average Volume (20 Days) | 877,624 |
Short Selling Information
The latest short interest is 2.60 million, so 5.96% of the outstanding shares have been sold short.
| Short Interest | 2.60M |
| Short Previous Month | 3.13M |
| Short % of Shares Out | 5.96% |
| Short % of Float | 6.49% |
| Short Ratio (days to cover) | 2.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.62M |
| Pretax Income | -31.75M |
| Net Income | -35.52M |
| EBITDA | -35.20M |
| EBIT | -35.62M |
| Earnings Per Share (EPS) | -$1.58 |
Full Income StatementBalance Sheet
The company has $22.12 million in cash and $17.74 million in debt, giving a net cash position of $4.38 million or $0.10 per share.
| Cash & Cash Equivalents | 22.12M |
| Total Debt | 17.74M |
| Net Cash | 4.38M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | 11.46M |
| Book Value Per Share | 0.43 |
| Working Capital | 9.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.05 million and capital expenditures -$439,000, giving a free cash flow of -$29.49 million.
| Operating Cash Flow | -29.05M |
| Capital Expenditures | -439,000 |
| Free Cash Flow | -29.49M |
| FCF Per Share | -$0.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |